헤더 로고

• All
• Day 1: March 26 (Thu)
• Day 2: March 27 (Fri)
• Day 3: March 28 (Sat)

Day 1: March 26 (Thu)

• Advances and Insights in Molecular Monitoring for Myeloproliferative Neoplasms Hsin-An Hou
  National Taiwan University Hospital, Taiwan CV
• Recent Therapeutic Advances in Early MF Winnie Teo
  Alexandra Hospital, Singapore CV
• Optimizing Treatment Strategies in Higher MF and Beyond Sung-Eun Lee
  College of Medicine, The Catholic University of Korea, Korea CV

Day 1: March 26 (Thu)

• Recent Advances in the Diagnosis and Management of Acquired Hemophilia A Shin Young Hyun
  Yonsei University College of Medicine, Korea CV
• Clinical Advances and Challenges in Gene Therapy Ben Samelson-Jones
  The Children's Hospital of Philadelphia, USA CV
• Role of Bispecific Antibody in Hemophilia Claude Négrier
  University of Lyon, France CV

Day 1: March 26 (Thu)

• Integration of MRD and Genetics as a Therapeutic Guidepost in ALL Anthony Moorman
  Newcastle University, UK CV
• Modern Immunotherapeutics in B-ALL: BiTEs, ADCs, and Beyond Jae-Ho Yoon
  College of Medicine, The Catholic University of Korea, Korea CV
• Optimizing Frontline Therapy in Ph+ ALL: The Role of Ponatinib and Beyond Nicholas J. Short
  The University of Texas MD Anderson Cancer Center, USA CV

Day 1: March 26 (Thu)

• Mantle Cell Lymphoma Jaewon Hyung
  University of Ulsan College of Medicine, Korea CV
• Chronic Lymphocytic Leukemia Jongheon Jung
  National Cancer Center, Korea CV
• Marginal Zone Lymphoma Sang-A Kim
  Seoul National University College of Medicine, Korea

Day 1: March 26 (Thu)

• Leukemic Stem Cells in 2026: Hierarchies, Heterogeneity, and Therapeutic Resistance John E. Dick
  University Health Network, Canada CV

Day 1: March 26 (Thu)

• Targeted Treatment of Aggressive B-cell Lymphomas Wyndham H. Wilson
  National Cancer Institute, USA CV

Day 1: March 26 (Thu)

• Integrating Comprehensive Geriatric Assessment into Hematology Practice: Identifying Frailty and Optimizing Care for Older Adults Jung-Yeon Choi
  Seoul National University Bundang Hospital, Korea CV
• Redefining Risk in Elderly AML: The GA Approach Byung Sik Cho
  College of Medicine, The Catholic University of Korea, Korea CV
• Psycho-oncological Interventions in Geriatric Hematology: Enhancing Quality of Life Juhee Cho
  Samsung Advanced Institute for Health Sciences & Technology, Korea

Day 1: March 26 (Thu)

• Affinity Tuning and Cytokine Modulation in CAR-T and CAR-NK Therapy Challice Bonifant
  Johns Hopkins University School of Medicine, USA CV
• Lessons from Hemophagocytic Lymphohistiocytosis: Taming the Cytokine Storm in CAR-T Cell Therapy Michael B. Jordan
  Cincinnati Children’s Hospital Medical Center, USA
• Myeloid Cells as Mediators of Cell Therapy: From Suppression to Activations Seunghee Kim-Schulze
  Icahn School of Medicine at Mount Sinai, USA CV

Day 1: March 26 (Thu)

• FLT3 Positive AML Ik-Chan Song
  Chungnam National University College of Medicine, Korea CV
• B-cell ALL with High Risk Features in Adults Dong Won Baek
  Kyungpook National University School of Medicine, Korea CV
• Understanding and Clinical Approach to Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Hee Young Ju
  Sungkyunkwan University School of Medicine, Korea CV

Day 1: March 26 (Thu)

• Insights into DDX41 Mutations: Relatively Common Genetic Aberrations in Korean MDS Patients Hongtae Kim
  Ulsan National Institute of Science and Technology, Korea CV
• Few Drug Approvals in MDS: Lessons and Insights from a Decade of Clinical Trials Maximilian Stahl
  Yale University School of Medicine, USA CV
• Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes Valeria Santini
  University of Florence, Italy CV

Day 1: March 26 (Thu)

• Recent Advances in the Genetics of Telomere Biology Disorders Sharon A. Savage
  National Institutes of Health, USA
• Role of Clonal Hematopoiesis in the Short Telomere Syndromes Kristen E. Schratz
  Johns Hopkins University School of Medicine, USA CV
• Dyskeratosis Congenita and Related Telomere Biology Disorders Inderjeet Dokal
  Queen Mary University of London, UK CV

Day 1: March 26 (Thu)

• Next-Generation Effector Cells in Myeloma Immunotherapy Hyunsoo Cho
  Seoul National University Hospital, Korea CV
• Natural Killer Cell-Based Immunotherapy in Multiple Myeloma Seung-Hwan Lee
  University of Ottawa, Canada CV
• Resistant Mechanisms and Newer Immunogenic Targets in Relapsed or Refractory Multiple Myeloma Marta Chesi
  Mayo Clinic, USA CV

Day 1: March 26 (Thu)

• Procedures and Interpretation of Bone Marrow Examination Seung Yeob Lee
  Jeonbuk National University Medical School, Korea CV
• Diagnostic and Monitoring Approaches Focused on Minimal Residual Disease Miyoung Kim
  University of Ulsan College of Medicine, Korea
• Blood Bank Testing before and after Hematopoietic Stem Cell Transplantation Dong Wook Jekarl
  College of Medicine, The Catholic University of Korea, Korea CV

Day 2: March 27 (Fri)

• Microbial Molecules as Emerging Biomarkers in Hematologic Diseases Christoph K. Stein-Thoeringer
  University Clinic Tübingen, Germany CV
• Gut Microbiome as a Predictive Biomarker and Emerging Intervention Target in DLBCL Woorim Kang
  Kangwon National University, Korea CV
• Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy Jonathan U. Peled
  Memorial Sloan Kettering Cancer Center, USA CV

Day 2: March 27 (Fri)

• A Personalized Approach to Immune Therapies for Cancer: One Drug, One Patient Larry W. Kwak
  City of Hope, USA CV
• Paradigm Shift of DLBCL Treatment Based on Bispecific Abs Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea
• Paradigm shift of DLBCL Treatment Based on MRD-Driven Approach Ash A. Alizadeh
  Stanford University, USA CV

Day 2: March 27 (Fri)

• Iron Deficiency & Iron Metabolism Jeong-Ok Lee
  Seoul National University College of Medicine, Korea
• Hereditary Hemolytic Anemia Heewon Chueh
  Inje University Haeundae Paik Hospital, Korea CV
• Cold Agglutinin Disease Dae-Ho Choi
  Sungkyunkwan University School of Medicine, Korea CV

Day 2: March 27 (Fri)

• The Present and Future of Hematopoietic Stem Cell Gene Therapies Cynthia E. Dunbar
  National Institutes of Health, USA CV

Day 2: March 27 (Fri)

• Menin Inhibitors and Epigenetic Therapy in KMT2A-rearranged ALL Elisabeth Salzer
  St. Anna Children's Hospital, Austria
• Virus-specific and Next-generation T-cell Therapy in Pediatric Hematologic Malignancy Catherine Bollard
  Children’s National Hospital, USA
• Pediatric Cancer Survivorship and Long-Term Toxicities Sharon M. Castellino
  Emory University School of Medicine, USA CV

Day 2: March 27 (Fri)

• Leukemia Stem Cells, Clonal Evolution, and Immune Evasion in AML: Translational Insights and Therapeutic Opportunities Ravindra Majeti
  Stanford University, USA CV
• Menin Inhibition in AML: Evolving Frontiers in Targeted Therapy Eytan M. Stein
  Memorial Sloan Kettering Cancer Center, USA CV
• HMA + Venetoclax + Targeted Agents: Clinical Evidence and Future of Triplet Therapy in AML Tapan Kadia
  The University of Texas MD Anderson Cancer Center, USA CV

Day 2: March 27 (Fri)

• Real-World Effectiveness of Immunotherapy in Hematologic Malignancies: Evidence from Big Data Sung-Soo Park
  College of Medicine, The Catholic University of Korea, Korea CV
• Digital Healthcare Innovation: Real-World Applications of Big Data and AI Yoon Sup Choi
  Digital Healthcare Partners, Korea CV
• Wise Hematology Life: Use of AI Ki-Hyun Jeon
  Seoul National University College of Medicine, Korea CV

Day 2: March 27 (Fri)

• Real World Long Term TPO-RA: Sustaining Remission or Time to Stop? Nichola Cooper
  Imperial College Healthcare NHS Trust, UK
• A New Chapter in ITP management - Updated trials Jun Ho Jang
  Sungkyunkwan University School of Medicine, Korea
• Caplacizumab and the Changing Landscape of TTP Management Shruti Chaturvedi
  Johns Hopkins University School of Medicine, USA CV

Day 2: March 27 (Fri)

• AL Amyloidosis: A Comprehensive Update from Fundamentals to Emerging Therapies Efstathios Kastritis
  National and Kapodistrian University of Athens, Greece CV
• Monoclonal Gammopathy and the Kidney: A Comprehensive Approach to MGRS Nelson Leung
  Mayo Clinic, USA CV
• POEMS Syndrome: From Longitudinal Clinical Experience to Translational Insights Emiko Sakaida
  Chiba University Hospital, Japan CV

Day 2: March 27 (Fri)

• CRS and ICANS: Early Detection and Personalized Management Jinchul Kim
  Inha University College of Medicine, Korea CV
• Prolonged Cytopenia after TCEs: Mechanisms, Biomarkers, and Risk Stratification Sang Eun Yoon
  Sungkyunkwan University School of Medicine, Korea CV
• Preventing Infections in TCEs: Risk Stratification and Prophylaxis Ja Min Byun
  Seoul National University College of Medicine, Korea CV

Day 3: March 28 (Sat)

• Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan Motoko Yamaguchi
  Mie University Graduate School of Medicine, Japan CV
• Research Progress of NK/ T-Cell Lymphoma: Experience from China Huangming Hong
  Sichuan Cancer Hospital, China CV
• Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea Seok Jin Kim
  Sungkyunkwan University School of Medicine, Korea CV

Day 3: March 28 (Sat)

• Clonal Evolution from Germline to Malignancy: Timing and Mechanisms Jyoti Nangalia
  University of Cambridge, UK CV
• Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management Marc H.G.P. Raaijmakers
  Erasmus MC Cancer Institute, The Netherlands
• Germline Predisposition Genes in Lymphoid Malignancies Susan L. Slager
  Mayo Clinic, USA

Day 3: March 28 (Sat)

• Immunological Landscape of CML Kyung-Mi Lee
  Korea University College of Medicine, Korea
• Integrating Biomarkers to Predict Response to TKIs Sin Tiong Ong
  Duke-NUS Medical School, Singapore CV
• Drug Combination to Overcome Resistance Delphine Rea
  Hôpital Saint-Louis, France CV

Day 3: March 28 (Sat)

• Vaccination and Infection Prevention Seong Jin Choi
  Seoul National University College of Medicine, Korea CV
• Cardiotoxicity: Risk Assessment and Prevention Hyukjin Park
  Chonnam National University Medical School, Korea CV
• Chemotherapy-induced Peripheral Neuropathy Young Woo Jeon
  College of Medicine, The Catholic University of Korea, Korea

Day 3: March 28 (Sat)

• High-risk Multiple Myeloma in 2026: Early Intervention, MRD-driven Therapy, and Beyond Philippe Moreau
  University Hospital of Nantes, France CV